Category: Earnings

Earnings

Polypore International (NYSE:PPO) – Fourth Quarter Earnings Review

Polypore (NYSE:PPO) reported adjusted EPS from continuing operations of $0.31 (down 14%), above the consensus estimate of $0.29. The $0.31 figure excludes $0.87 associated with the operations and gain on sale of the Microporous business, which was reported in discontinued operations. During the quarter, EPS were unfavorably affected by about $0.04-$0.05 due to a higher-than-expected tax rate. Polypore reported consolidated revenue of $169 million (up … Continue reading Polypore International (NYSE:PPO) – Fourth Quarter Earnings Review

Richard Atkins
Analysis, Earnings

Chart Industries, Inc. Weak Guidance Highlights Q4 Results

Chart Industries’ (NASDAQ:GTLS) overall fourth quarter 2013 EPS and awards were mostly in line with expectations; however, we believe this will be overshadowed by lower-than-expected 2014 EPS guidance ($3.10-$3.50 versus consensus $3.67) and more subdued market commentary regarding near-term growth prospects. There was already a somewhat downward bias to 2014 consensus EPS, the more cautious market commentary about near-term growth prospects may come as a … Continue reading Chart Industries, Inc. Weak Guidance Highlights Q4 Results

John Bellich
Diversified Tech, Earnings

Midday Gainers: Intermune Doubles; Tekmira Advances to Record High; Diamond Rock Hits 6-Year High

InterMune (NASDAQ:ITMN) more than doubled Tuesday to its highest value since May 2011 after saying data from a phase 3 trial showed its Pirfenidone drug significantly reduced the progression of idiopathic pulmonary fibrosis. Near midday, ITMN had jumped 126.6% at $31.63 per share in recent trading. Earlier it hit $37.22. Also, significant treatment effects were demonstrated on both of the key secondary endpoints of six-minute … Continue reading Midday Gainers: Intermune Doubles; Tekmira Advances to Record High; Diamond Rock Hits 6-Year High

Jayne Crisman
Consumer Goods, Earnings, Tech IPO

Zulily (NASDAQ:ZU) Posts Stunningly Good Fourth Quarter

Zulily (NASDAQ:ZU) needed to deliver upside to consensus projections in the fourth quarter, and the magnitude of the top- and bottom-line beat was more than adequate.. The doubling of the active customer base year-to-year is encouraging, and the leverage on marketing spending highlights that there is still significant untapped demand. Flow-through to profitability on higher revenues was exceptional; adjusted EBITDA were double consensus estimates. The … Continue reading Zulily (NASDAQ:ZU) Posts Stunningly Good Fourth Quarter

Richard Atkins
BioTech, Earnings, Software

Morning Watchlist: Apollo Investment, XOMA, Taminco, Hyperion Pharma

Shares in Apollo Investment Corporation (NASDAQ:AINV) dropped more than 5% pre-market after the company said it has priced a public offering of 12.0 million shares. Underwriters have the option to buy an additional 1.8 million shares. The company didn’t give the price of the offer. XOMA Corp (NASDAQ:XOMA) is moving nearly 5% higher after the drug maker announced that gevokizumab, the company’s IL-1 beta modulating … Continue reading Morning Watchlist: Apollo Investment, XOMA, Taminco, Hyperion Pharma

Adam Keintzel
Diversified Tech, Earnings

Aircastle (NYSE:AYR) Q4 Results Top Expectations; Bloomin Brands (NASDAQ:BLMN) Beats Street

Aircastle (NYSE:AYR) reported Q4 earnings and sales that topped analysts expectations and struck a deal worth $900 million to buy eight Boeing 777-300ER aircraft from LATAM Airlines Group and then to lease them back. The buyer, leaser and seller of aircraft back to commercial airlines said adjusted net income rose to $0.68 per share from $0.52 the year earlier, coming in well ahead of the … Continue reading Aircastle (NYSE:AYR) Q4 Results Top Expectations; Bloomin Brands (NASDAQ:BLMN) Beats Street

Colin Pettis